Investigation Of Factors Affecting Hand Functions in Nonambulatory Patients With Duchenne Muscular Dystrophy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03521271|
Recruitment Status : Completed
First Posted : May 10, 2018
Last Update Posted : May 10, 2018
|Condition or disease|
|Duchenne Muscular Dystrophy|
Duchenne Muscular Dystrophy (DMD) is the most common neuromuscular disease seen in childhood. DMD is an X linked recessive disorder. DMD is characterized by complete or partial (<3%) deficiency of the cell membrane protein dystrophin.
Dystrophin deficiency results in a permanent deterioration of muscle fibers. This leads to a progressive decrease in muscle strength and functional abilities. The precise mechanism of how the defect of dystrophin leads to degeneration of muscle fibers remains uncertain, but cytoskeletal deterioration, sarcolemmal instability and abnormal calcium homeostasis are thought to play a role in this degeneration.
These patients have symptoms such as limb proximals and progressive muscle weakness in the trunk, gait abnormalities, Gower's sign, various degrees of restriction in daily living activities, and frequent falls. The majority of patients have elevated serum creatine kinase or elevated liver transaminases and less frequently language or general developmental retardation.
Walking ability of this children begins to deteriorate between the ages of 3-6. These patients are generally dependent on wheelchair aged 10-12 years. The loss of walking is the milestone in terms of the progression of the disease. The use of electric wheelchairs limits arm functions such as lengthening and lifting during the late phase of the illness (when the ambulance has been lost and the ambulance is being continued with the wheelchair).
Patients with DMD have an average life span of 30 years with spinal surgery and ventilation support. They spend most of their lives dependent on the wheelchair and need functional use of the upper limbs to maintain the best possible level of independence in their daily life activities throughout their lifetimes.
Although muscle weakness in the proximal limbs is the first finding of the disease, the influence of upper extremity functions gives symptoms after 8 years of age and has a great influence on the level of independence of DMD patients in life since this process. For this reason, rehabilitation approaches for the protection of upper extremity functions from the early period of the disease are of great importance.Effective interventions are necessary to achieve this goal and these variables must be considered when making clinical decisions.
Patients with adult DMD have been shown to be able to perform important functional activities with limited distal motor function in the late phase of disease, but tend to lose these capacities as muscle strength decreases. For this reason, determining the factors (grip strength, thumb opposition, upper extremity joint range of motion, upper extremity muscle strength, etc.) that may affect hand functions, which is an important component in maintaining upper extremity functioning, and how these factors are related to the general functions of the upper extremity it is crucial that this disease leads to physiotherapy rehabilitation programs to be implemented.
|Study Type :||Observational|
|Actual Enrollment :||23 participants|
|Official Title:||Investigation Of Factors Affecting Hand Functions in Nonambulatory Patients With Duchenne Muscular Dystrophy|
|Actual Study Start Date :||April 5, 2017|
|Actual Primary Completion Date :||January 26, 2018|
|Actual Study Completion Date :||January 26, 2018|
- Brooke Upper Extremity Functional Classification (1-6) [ Time Frame: 2 minutes ]
Children's functional levels were assessed with Brooke Upper Extremity Functional Classification (BUEFS) and children with a BUEFS score between 1-5 were included in the study.
- Starting with arms at sides, can abduct arms in a full circle until they touch above head
- Can raise arms above head only by flexing elbow or using accesory muscles
- Cannot raise arms above head but can raise a glass of water to mouth (using both hands if necessary)
- Can raise hands to mouth but cannot raise a glass of water to mouth
- Cannot raise hand to mouth but can use hands to hold pen or pick up pennies from table
- Cannot raise hands to mouth and has no useful function of hands
- Passive joint range of motion [ Time Frame: 10 minutes ]Passive range of motions were assessed with goniometer and recorded limitations.
- Upper extremity muscle strength [ Time Frame: 20 minutes ]Hand held dynamometer
- Thumb opposition [ Time Frame: 2 minutes ]
Thumb opposition was assessed by Kapandji score (1-10). Score Location achieved
- Radial side of the proximal phalanx of the 2nd phalanx
- Radial side of the middle phalanx of the 2nd phalanx
- Tip of the 2nd phalanx
- Tip of the 3th phalanx
- Tip of the 4th phalanx
- Tip of the 5th phalanx
- Distal interphalangeal joint crease of the 5th phalanx
- Proximal interphalangeal joint crease of the 5th phalanx
- Metacarpophalangeal joint crease of the 5th phalanx
- Distal palmar crease
- Lateral, tripod, two-point pinch strength [ Time Frame: 3 minutes ]Pinchmeter
- Performance of the upper extremity [ Time Frame: 15 minutes ]
Performance of the Upper Limb (PUL) (0-74) is including three dimension:
- Shoulder dimension (0-16)
- Elbow dimension (0-34)
- Distal dimension (0-24)
- Hand function [ Time Frame: 3 minutes ]ABILHAND-Kids (0-36)
- Activity limitations [ Time Frame: 3 minutes ]ACTIVLIM (0-36)
- Gross grip strength [ Time Frame: 2 minutes ]Hand dynamometer
- Quality of life assessment of children (0-100) [ Time Frame: 5 minutes ]PedsQL-Child report
- Quality of life assessment of parents (0-100) [ Time Frame: 5 minutes ]PedsQL-Parent report
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03521271
|Ankara, Samanpazarı/Ankara, Turkey, 06100|